Mechanism of Action
GALR2 and GALR3 Receptor Agonism
Spexin activates galanin receptors GALR2 and GALR3 with high affinity. These Gi-coupled receptors inhibit cAMP and activate MAPK/ERK pathways. In hypothalamic energy balance circuits, GALR2/3 activation suppresses appetite and activates sympathetic outflow to brown adipose tissue, increasing thermogenesis. GALR3 in limbic circuits contributes to spexin's anti-anxiety and antidepressant-like effects.
Metabolic Regulation
Spexin suppresses insulin and glucagon secretion from pancreatic islets through GALR2/3 on alpha and beta cells. This reduces both postprandial insulin overshoot and fasting glucagon excess, potentially improving insulin sensitivity. Spexin also inhibits adipogenesis and promotes lipolysis in adipocytes, explaining the correlation between low spexin and increased adiposity.
Research Summary
Obesity and Metabolic Syndrome
HumanHuman observational studies consistently find plasma spexin levels are 50-70% lower in obese individuals versus lean controls, and inversely correlate with BMI, insulin resistance, and leptin/" class="wiki-internal-link">leptin levels. Weight loss interventions restore spexin levels, and the degree of spexin elevation correlates with metabolic improvement. This tight inverse relationship with obesity has motivated spexin as a potential biomarker and therapeutic target.
Appetite and Weight Loss
AnimalICV and peripheral spexin injections reduce food intake in rats and zebrafish models through hypothalamic GALR2/3 signaling. Chronic spexin treatment reduces body weight and fat mass without reducing lean mass. In diet-induced obese mice, spexin treatment reversed obesity and improved metabolic parameters.
Cardiovascular Effects
AnimalSpexin produces vasodilatory and natriuretic effects in the kidney through GALR2/3, reducing blood pressure in hypertensive animal models. These cardiovascular properties, combined with the metabolic effects, position spexin as a multi-target metabolic-cardiovascular peptide analogous to GLP-1.
Calculate your Spexin dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Appetite / weight research | 10-100 nmol/kg | Daily x 2-4 weeks | Subcutaneous or ICV |
| Metabolic biomarker studies | N/A (measurement) | Fasting plasma sample | Blood draw (human observational) |
Spexin research is at a preclinical stage for therapeutic development. Human data consists of observational studies; no interventional human trials of exogenous spexin have been completed.
Interactions
Safety Profile
Animal studies have not identified significant adverse effects at research doses. Spexin was discovered recently (confirmed 2013) and its complete pharmacological and toxicological profile is still being established. The GALR2/3 mechanism is generally well-tolerated based on galanin receptor biology. No human interventional safety data exists. The strong metabolic biomarker correlations in humans suggest physiological relevance that warrants accelerated clinical investigation.
References
- [1]Mirabeau O, et al. Identification of novel peptide hormones in the human proteome by hidden Markov model screening. Genome Res. 2007;17(3):320-327.
- [2]Walewski JL, et al. Spexin is a novel human peptide that reduces adipocyte uptake of long chain fatty acids and causes loss of body weight in rodents. FASEB J. 2014.
- [3]Behera S, et al. Spexin levels are reduced in obese humans and linked to insulin resistance. Endocrinology. 2019.